Case Report: Identification of a novel STAT3 mutation in EBV-positive inflammatory follicular dendritic cell sarcoma

Megan C Ramsey; Peter J B Sabatini; Geoffrey Watson; Tanya Chawla; Michael Ko; Ali Sakhdari

doi:10.3389/fonc.2023.1266897

Case Report: Identification of a novel STAT3 mutation in EBV-positive inflammatory follicular dendritic cell sarcoma

Front Oncol. 2023 Oct 26:13:1266897. doi: 10.3389/fonc.2023.1266897. eCollection 2023.

Authors

Megan C Ramsey^{1

2}, Peter J B Sabatini^{2

3

4}, Geoffrey Watson⁵, Tanya Chawla⁶, Michael Ko⁷, Ali Sakhdari^{1

2}

Affiliations

¹ Hematopathology Department, Toronto General Hospital, Toronto, ON, Canada.
² Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
³ Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
⁴ Advanced Molecular Diagnostic Laboratory, Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁵ Medical Oncology, Mount Sinai Hospital, Toronto, ON, Canada.
⁶ Joint Department of Medical Imaging, Mount Sinai Hospital, Toronto, ON, Canada.
⁷ Thoracic Surgery, Unity Health Network, St Joseph's Hospital Site, Toronto, ON, Canada.

Abstract

EBV-positive inflammatory follicular dendritic cell sarcoma (EBV+ IFDCS) is an uncommon disease primarily observed in Asia. It is characterized by the development of tumors believed to originate from follicular dendritic cells (FDC). The consistent association between this condition and clonal EBV infection suggests EBV's involvement as an etiological factor. However, diagnosing EBV+ IFDCS can be challenging due to its morphological variability and diverse immunohistochemical staining patterns. The genetic characteristics of EBV+ IFDCS remain insufficiently understood. To address this knowledge gap, we present a case study of a 47-year-old male patient diagnosed with EBV+ IFDCS. We utilized a Next-generation sequencing (NGS) platform to investigate the genetic profile of the tumor cells. We identified a single pathogenic mutation (G618R) in the STAT3 gene. This finding provides valuable insights into the genetic alterations associated with EBV+ IFDCS and potentially contributes to our understanding of the disease's pathogenesis.

Keywords: Epstein Barr virus (EBV); STAT3; chemotherapautic; inflammatory follicular dendritic cell sarcoma; mutational profile.

Publication types

Case Reports

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.